IBRX Immunitybio Inc
Company Analysis
Latest News
ImmunityBio Reports 71% Complete Response Rate in Bladder Cancer Trial
ImmunityBio announced the publication in the Journal of Urology of long-term results from its Phase 2/3 trial of ANKTIVA plus BCG in patients with a type of...
🔴 Immunitybio is trading 5% down today amid biotech sector weakness
Immunitybio is trading 4.8% lower at $9.52, with biotech-sector weakness the clearest supporting context but no confirmed company-specific negative...
🟢 Immunitybio is trading 5.65% up today after FDA expanded ANKTIVA approval for bladder cancer treatment
Immunitybio is trading at $10.47 (+5.65%) after the FDA expanded ANKTIVA’s approval to cover BCG-unresponsive bladder cancer with papillary-only tumors. • The...
IBRX Receives Expanded FDA Approval for ANKTIVA in Bladder Cancer Treatment
ImmunityBio announced on October 14, 2026, that the U.S. Food and Drug Administration (FDA) has expanded the approved indication for its drug, ANKTIVA®, used...
🟢 Immunitybio is trading 5% up today after FDA expands Anktiva for papillary-only bladder cancer
Immunitybio is trading 5.05% up at $10.29 alongside the FDA’s October 14, 2026 expansion of Anktiva’s approval. - The significant company-specific milestone...
🔴 Immunitybio is trading 5.3% down; reason remains unclear
Immunitybio is trading at $9.59, down 5.29%, and the reason for the October 13 decline remains unclear. - No clear company-specific announcement or event...
🔴 Immunitybio is trading 4% down
Immunitybio is trading at $10.09, down 4.04% in the live session on October 12, 2026; no clear company-specific catalyst was identified. - Major indices were...
🟢 Immunitybio is trading 5% up — no clear catalyst identified
Immunitybio is trading at $10.40, up +4.99%, during the October 9, 2026 session, with no clear company-specific catalyst identified for the gain. -...
🔴 Immunitybio is trading 4.19% down as biotech shares come under pressure
Immunitybio is trading 4.19% down at $9.95 now, with biotech weakness the clearest available context for the decline. - No clear company-specific explanation...
🟢 Immunitybio is trading 10% up today with broader markets higher; catalyst remains unclear
Immunitybio is trading 10.05% higher at $10.21, with no clear company-specific announcement explaining the October 2 move. - The company is scheduled to...
🟢 Immunitybio is trading 7% up today amid broader market gains
Immunitybio is trading at $9.89, up 6.63%, amid broader market strength. - No clear company-specific announcement explaining the rise surfaced in the...
🟢 Immunitybio is trading 11% up with no clear company-specific catalyst identified
Immunitybio is trading at $9.79, up +10.82%, with no clear company-specific announcement identified to explain its September 30 move. - Recent coverage...
🟢 Immunitybio is trading 5.4% up
Immunitybio is trading at $9.31, up +5.44%, while the reason for the September 30 move remains unclear. - No clear company-specific announcement explaining...
🟢 Immunitybio is trading 4.11% up
Immunitybio is trading 4.11% higher now at $8.87 on September 29, 2026, with no clear company-specific catalyst identified. - Recent coverage has focused on...
🟢 Immunitybio is trading 4.3% up
Immunitybio is trading at $8.80, up +4.32%, on September 28, 2026, with no clear company-specific announcement identified to explain the gain. - Recent...
ImmunityBio Rallies Nearly 10% on Turkey Expansion Plans
ImmunityBio founder Dr. Patrick Soon-Shiong met with Turkish President Recep Tayyip Erdogan to discuss the company’s planned expansion into Turkey’s cancer...
🔴 Immunitybio is trading 4.38% down today while biotech sector gains
Immunitybio is trading 4.38% down at $8.88, with no new company announcement or confirmed fundamental catalyst clearly explaining the September 23 decline. -...
🟢 Immunitybio is trading 10.71% up today amid intensified retail speculation over Nant's blockchain plans
Immunitybio is trading at $9.36, up +10.71%, as retail speculation intensifies around Nant’s planned blockchain and tokenized-stock platform. - No confirmed...
🟢 Immunitybio is trading 4.44% up today amid retail speculation over Nant’s blockchain plans
Immunitybio is trading $8.82 (+4.44%) amid retail speculation following Patrick Soon-Shiong’s discussion of Nant’s planned blockchain and tokenized-stock...
🟢 Immunitybio is trading 10.18% up today as biotech shares rally after Fed decision
Immunitybio is trading 10.18% up at $8.71 as biotechnology shares and broader markets rally after the September 16, 2026 Federal Reserve decision. - The...